WCBA
JAZZ icon

Weaver C. Barksdale & Associates’s Jazz Pharmaceuticals JAZZ Stock Holding History

Weaver C. Barksdale & Associates’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-15,500
Closed -$2.73M – 550
2015
Q2 		$2.73M Hold
15,500
– – 2% 17
2015
Q1 		$2.68M Hold
15,500
– – 2.01% 16
2014
Q4 		$2.54M Hold
15,500
– – 2.04% 14
2014
Q3 		$2.49M Buy
+15,500
New +$2.38M 2.05% 12

Other funds holding JAZZ

PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
WBC
Westpac Banking Corp Sydney, Australia $1.44B AUM 28.5% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Weaver C. Barksdale & Associates's JAZZ Position: Q3 2015 in Review

Weaver C. Barksdale & Associates sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2015, closing a stake of 15,500 shares — an estimated $2.73M sold.

Weaver C. Barksdale & Associates first reported a position in JAZZ in Q3 2014 and held it in 4 quarters. The position peaked at $2.73M in Q2 2015. 360 funds tracked by Wall St. Rank hold JAZZ as of Q3 2015.

  • Weaver C. Barksdale & Associates reported no remaining Jazz Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
  • Weaver C. Barksdale & Associates sold 15,500 Jazz Pharmaceuticals shares in Q3 2015, an estimated $2.73M.
  • Weaver C. Barksdale & Associates first reported a position in Jazz Pharmaceuticals in Q3 2014 and held it in 4 quarters.
  • Weaver C. Barksdale & Associates's Jazz Pharmaceuticals position peaked at $2.73M in Q2 2015.
  • 360 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2015.

Based on Weaver C. Barksdale & Associates's 13F filing for Q3 2015, filed 7 Oct 2015.